SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): June 29, 2009 (June 25,
2009)
CHEMBIO
DIAGNOSTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
|
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
|
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
|
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01. REGULATION
FD DISCLOSURE.
On June
25, 2009, the Company issued a press release entitled “Chembio Awarded Three
Year $3MM NIH SBIR Phase II Grant to Complete DPP® Test for Human Leptospirosis
”. A copy of the press release is furnished herewith as
Exhibit 99.1.
On June
29, 2009, the Company issued a press release entitled “Chembio Presenting
DPP® Syphilis at ISSTDR Congress ”. A copy of the press release is
furnished herewith as Exhibit 99.2.
The
information in this Item 7.01 of this Form 8-K is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, or otherwise subject to the liabilities of that section. The
information in this Item 7.01 of this Form 8-K also shall not be deemed to be
incorporated by reference into any filing under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, except to the extent that the
Company specifically incorporates it by reference.
ITEM
9.01. FINANCIAL
STATEMENTS AND EXHIBITS
Exhibits.
|
99.1
|
Press
Release entitled “Chembio Awarded Three Year $3MM NIH
SBIR Phase II Grant to Complete DPP® Test for Human Leptospirosis”
dated June 25, 2009.
|
|
99.2
|
Press
release entitled “Chembio Presenting
DPP® Syphilis at ISSTDR Congress ” dated June 29, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
June 29,
2009 Chembio
Diagnostics, Inc.
By: /s/ Lawrence A.
Siebert
Lawrence A. Siebert
Chief Executive Officer
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release entitled “Chembio Awarded Three Year $3MM NIH
SBIR Phase II Grant to Complete DPP® Test for Human Leptospirosis”
dated June 25, 2009.
|
|
99.2
|
Press
release entitled “Chembio Presenting
DPP® Syphilis at ISSTDR Congress” dated June 29, 2009.
|